AbbVie Ltd. wishes to announce that Humira (adalimumab) injection has received approval for the treatment of active moderate to severe hidradenitis suppurativa (HS), also known as acne inversa, in adults with an inadequate response to conventional systemic HS therapy. Humira is a tumour necrosis factor (TNF) antagonist, binding specifically to TNF and blocking its interaction with cell surface TNF receptors. It also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration. Humira has already been approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, plaque psoriasis, paediatric plaque psoriasis, Crohn’s disease, paediatric Crohn’s disease, and ulcerative colitis (see SPC). Humira 40mg solution for injection is available as a pre-filled syringe, pre-filled pen and vial presentation. For further information please contact AbbVie Ltd. at (01) 4287900.
↧